Parkinson’s disease is a neurodegenerative disorder that affects body movements. In simpler words, the disease disturbs brain functioning by slowly decreasing the production of a neurotransmitter called dopamine. Over time, with decreasing levels of dopamine, a person loses the ability to regulate body movements, emotions, etc. Parkinson’s disease drugs help balance diminishing levels of dopamine.
Browse full research report @ https://goo.gl/nCvKqa
Common symptoms of the disease include:
- Fatigue
- Slow bodily movements
- Co-ordination problems
- Little or no facial expressions
- Poor balance
- Difficulty walking
- Difficulty thinking and understanding
- Impaired voice
- Amnesia
New FDA-approved Drug Shows Promising Result in Clinical Trials
The Parkinson’s disease drugs market, at present, has great scope for growth owing to high unmet clinical needs resulting from lack of Disease Modifying Drugs (DMDs). Thus, many key players are focusing on research and development activities and clinical trials along with novel product launches. This may augment the growth of the market in future.
Recently, Newron Pharmaceuticals SpA received FDA approval for Xadago (safinamide) for the treatment of Parkinson’s disease. The effectiveness of Xadago in treating the disease was shown in a clinical trial of a group of patients. This study was conducted on patients who were taking levodopa and were having “off” time, where a patient’s medicines stop working, further aggravating disease symptoms.
The study showed that patients taking Xadago had more “on” time, where disease symptoms are reduced, without any involuntary uncontrolled movements.
Market Overview
As per the findings of a new study made available by Radiant Insights, Inc., the worldwide Parkinson’s disease drugs market is anticipated to witness strong growth during the forecast period (from 2017 to 2021). Increasing geriatric population across the world is expected to drive the growth of the global market over the next few years. Moreover, many firms, such as International Stem Cell Corp., are focusing on clinical trials for stem cell therapies for the treatment of Parkinson’s. Hence, this therapy is likely to provide significant growth prospects for the development of the global market.
Teva Pharmaceutical Industries Ltd.; Salix Pharmaceuticals, Inc.; Impax Laboratories, Inc.; Orion Corp.; Novartis International AG; and GlaxoSmithKline PLC. are some of the prominent firms operating in the global Parkinson’s disease drugs market.
The Parkinson’s disease drugs market, at present, has great scope for growth owing to high unmet clinical needs resulting from lack of Disease Modifying Drugs (DMDs). Thus, many key players are focusing on research and development activities and clinical trials along with novel product launches. This may augment the growth of the market in future.
Recently, Newron Pharmaceuticals SpA received FDA approval for Xadago (safinamide) for the treatment of Parkinson’s disease. The effectiveness of Xadago in treating the disease was shown in a clinical trial of a group of patients. This study was conducted on patients who were taking levodopa and were having “off” time, where a patient’s medicines stop working, further aggravating disease symptoms.
The study showed that patients taking Xadago had more “on” time, where disease symptoms are reduced, without any involuntary uncontrolled movements.
Market Overview
As per the findings of a new study made available by Radiant Insights, Inc., the worldwide Parkinson’s disease drugs market is anticipated to witness strong growth during the forecast period (from 2017 to 2021). Increasing geriatric population across the world is expected to drive the growth of the global market over the next few years. Moreover, many firms, such as International Stem Cell Corp., are focusing on clinical trials for stem cell therapies for the treatment of Parkinson’s. Hence, this therapy is likely to provide significant growth prospects for the development of the global market.
Teva Pharmaceutical Industries Ltd.; Salix Pharmaceuticals, Inc.; Impax Laboratories, Inc.; Orion Corp.; Novartis International AG; and GlaxoSmithKline PLC. are some of the prominent firms operating in the global Parkinson’s disease drugs market.
No comments:
Post a Comment